iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IRadimed excels in Q4 2022, anticipates strong growth in 2023

IRadimed's Q4 2022 showcased exceptional performance with record revenues and strong earnings, setting the stage for continued growth.
While facing challenges such as margin pressures and tax expenses, the company's optimistic outlook for 2023 presents growth opportunities.
Strategic focus on revenue expansion, margin improvement, and cost management will be key to sustaining profitability and maximizing shareholder value.
Investors can look forward to potential earnings growth and market positioning strength in the upcoming year.

IRadimed reports record revenue and earnings growth, anticipates FDA clearance

IRadimed's Q1 2023 performance was strong, with record revenue and earnings growth. Despite supply chain challenges, the company is optimistic about FDA clearance for a new product and expects pricing trends to remain favorable.

iRadimed posts record revenue and earnings, raises guidance optimistically

iRadimed delivered exceptional financial performance in Q2 2023, achieving record revenue and substantial earnings growth, driven by strong sales across all product categories.
The company's operational efficiency, margin expansion, and strategic initiatives position it well for sustained growth and profitability in the future.
With raised guidance, innovative product developments, and expanding market presence, iRadimed is poised for continued success and value creation for shareholders.
Investors can be optimistic about iRadimed's performance, as the company demonstrates resilience, growth potential, and a solid foundation for future expansion.

iRadimed reports record Q3 earnings, raises 2023 guidance optimistically

iRadimed (IRMD) delivered exceptional Q3 '23 results, with record revenue, earnings growth, and strong product sales, positioning the company for continued success.
While facing challenges in meeting Q4 '23 targets and securing regulatory approvals, iRadimed's proactive strategies and market opportunities offer avenues for sustained growth.
With raised guidance for 2023 and promising product developments, iRadimed has the potential to capitalize on its strengths and navigate industry challenges effectively.
Investors and stakeholders can look to iRadimed's performance, product innovation, and regulatory progress as indicators of the company's resilience and growth prospects.

iRadimed (IRMD) reports record Q4 revenue, eyes international expansion

iRadimed's Q4 2023 performance marked by record revenue, strong device sales, and margin challenges. The company's focus on product growth and international expansion presents opportunities for future revenue and earnings growth.

iRadimed (IRMD) posts record revenue and earnings growth in Q1 2024

iRadimed (IRMD) delivered strong financial performance in Q1 2024, driven by record revenue, earnings growth, and robust demand for MR patient monitor products.
Despite challenges such as submission delays and significant investment in a new facility, the company remains focused on innovation and shareholder value.
With opportunities for market expansion, product clearance, and operational enhancements, iRadimed is poised for continued growth and competitive strength in the medical device industry.

iRadimed (IRMD) achieves record Q2 earnings, eyes FDA clearance

iRadimed's Q2 2024 performance reflects robust revenue growth, improved margins, and enhanced operational efficiency, positioning the company for continued success.
While facing challenges in international sales and operational delays, iRadimed's focus on cost management and product development presents opportunities for future growth.
Overall, iRadimed's financial outlook remains positive, with strong cash flow, new product developments, and strategic initiatives driving long-term value for investors.

iRadimed posts record Q3 earnings, eyes new product launches

iRadimed's Q3 2024 performance reflects strong revenue growth, operational efficiency, and effective cost management.
While facing challenges in product clearance and sales transition, the company is well-positioned to capitalize on growth opportunities.
Strategic focus on new product launches and international market expansion could drive future revenue and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

iRadimed (IRMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Here's What Could Help iRadimed (IRMD) Maintain Its Recent Price Strength

IRadimed's (IRMD) CEO Roger Susi on Q1 2021 Results - Earnings Call Transcript

WINTER SPRINGS, Fla., April 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three months ended March 31, 2021.

IRADIMED CORPORATION Announces First Quarter 2021 Financial Results

iRadimed (NASDAQ:IRMD) announces its next round of earnings this Friday, April 30. Here is Benzinga's look at iRadimed's Q1 earnings report.

Earnings Outlook for iRadimed

WINTER SPRINGS, Fla., April 09, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2021 first quarter financial results before the market opens on Friday, April 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2021 First Quarter Financial Results Conference Call on April 30th

IRadimed's (IRMD) CEO Roger Susi on Q4 2020 Results - Earnings Call Transcript

WINTER SPRINGS, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market opens on Thursday, February 4th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2020 Fourth Quarter Financial Results Conference Call on February 4th

IRadimed Corporation (IRMD) CEO Roger Susi on Q3 2020 Results - Earnings Call Transcript

IRadimed Corporation's (IRMD) CEO Roger Susi On Q3 2020 Results - Quick Version Earnings Call Transcript

WINTER SPRINGS, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring system that are designed for use during MRI procedures, today announced financial results for the three and nine months ended September 30, 2020.

IRADIMED CORPORATION Announces Third Quarter 2020 Financial Results

IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate iRadimed (IRMD) to Report a Decline in Earnings: What to Look Out for

WINTER SPRINGS, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 third quarter financial results before the market opens on Friday, October 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2020 Third Quarter Financial Results Conference Call on October 30th

IRadimed Corp (IRMD) CEO Roger Susi on Q2 2020 Results - Earnings Call Transcript

WINTER SPRINGS, Fla., July  30, 2020  (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system and non-magnetic patient vital signs monitoring system that are designed for use during MRI procedures, today announced financial results for the three and six months ended June 30, 2020.

IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results

Earnings Preview: iRadimed (IRMD) Q2 Earnings Expected to Decline

WINTER SPRINGS, Fla., July  16, 2020  (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 second quarter financial results before the market opens on Thursday, July 30th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION to Hold 2020 Second Quarter Financial Results Conference Call on July 30th

WINTER SPRINGS, Fla., May  29, 2020  (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), announced today that its Board of Directors has appointed Roger Susi to resume his duties as the Company’s President and Chief Executive Officer after the departure of Leslie McDonnell, who separated from the Company effective May 28, 2020.

IRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer

Latest patent expands previous claims around IRADIMED’s wireless communication as used to remotely control an IV pump Latest patent expands previous claims around IRADIMED’s wireless communication as used to remotely control an IV pump

IRADIMED CORPORATION Announces Issuance of U.S. Patent

IRadimed's (IRMD) CEO Leslie McDonnell on Q1 2020 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.48%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

IRadimed (IRMD) Q1 Earnings Surpass Estimates

Shares of iRadimed (NASDAQ:IRMD) rose 0.2% after the company reported Q1 results.

Recap: iRadimed Q1 Earnings

Earnings Preview: iRadimed (IRMD) Q1 Earnings Expected to Decline

Expects first quarter 2020 revenue of $8.6 million to $8.7 million Expects first quarter 2020 revenue of $8.6 million to $8.7 million

IRADIMED CORPORATION Withdraws 2020 Financial Guidance Due to Uncertainties from the Effects of COVID-19

IRadimed's (IRMD) CEO Leslie McDonnell on Q4 2019 Results - Earnings Call Transcript

iRadimed (IRMD) delivered earnings and revenue surprises of 50.00% and -0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

News for iRadimed Stock (IRMD)